The research proposed by The University of Texas SPORE in Lung Cancer encompasses a broad range of lung cancer translational research activities, including studies in cell lines, xenografts and transgenic animal models, clinically and molecularly annotated tumor and other biospecimens, germline polymorphisms, and clinical trials. These studies will generate many different types of data, including clinical, epidemiological, biochemical, immunohistochemical, dose response, gene expression microarrays, sequencing, and more. The Core provides comprehensive expertise to ensure the statistical integrity, data integrity, data sharing, and data analysis of the studies performed by the SPORE, which are conducted at the University of Texas Southwestern Medical Center (UTSW), the M.D. Anderson Cancer Center (MDACC) and Ohio State University (OSU). The Core has a director at each institution (Xie at UTSW, Baladandayuthapani at MDACC, and Coombes at OSU) and has the flexibility to match personnel to the evolving needs of existing and developmental SPORE Projects. Members of the Core participate in monthly SPORE vide conferences linking researchers at UTSW in Dallas, TX, MDACC in Houston, TX and OSU in Columbus, Ohio, ensuring that proper consideration is taken of biostatistics and data management issues during all phases of SPORE experiments. The Core will develop and maintain systems for data storage, retrieval, analysis, and sharing. It will provide an interface for all SPORE investigators. The Core services are made possible by the accumulated experience, accumulated computer codes and resources, and by innovative, unique, sometimes customized approaches to solving the data analysis and interpretation challenges in the modern data centric research laboratory. To carry out its responsibilities, the Core has the following Specific Aims:
Aim 1 : To provide valid statistical designs of laboratory research, clinical trials and translational experiments arising from the ongoing research of the SPORE.
Aim 2 : To oversee and conduct the innovative statistical modeling, simulations, data analyses and data integration needed by the Projects, Developmental and Career Projects, and the other Cores to achieve their specific aims. A im 3: To ensure that the results of all Projects are based on well-designed experiments, appropriately interpreted, and to assist in the preparation of manuscripts describing these results. A im 4: To provide an integrated site for data storage and distribution for the SPORE Projects, particularly those with genome-wide and other data-dense Projects.

Public Health Relevance

The Biostatistics and Bioinformatics Core ensures that all experiments performed by the core are properly designed, and that the data collected by those experiments are stored safely, analyzed sensibly, and made available to other SPORE investigators (and ultimately to other lung cancer researchers) in order to further the ultimate goal of translating knowledge from the research lab into the clinic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA070907-16A1
Application #
8747071
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (M1))
Project Start
1996-09-30
Project End
2019-08-31
Budget Start
2014-09-23
Budget End
2015-08-31
Support Year
16
Fiscal Year
2014
Total Cost
$278,105
Indirect Cost
$55,727
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Skoulidis, Ferdinandos; Goldberg, Michael E; Greenawalt, Danielle M et al. (2018) STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov 8:822-835
Walser, Tonya C; Jing, Zhe; Tran, Linh M et al. (2018) Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. Cancer Res 78:1986-1999
Ferdosi, Shadi; Rehder, Douglas S; Maranian, Paul et al. (2018) Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, ?1-4 Branching, ?1-6 Branching, and ?2-6 Sialylation in Cancer. J Proteome Res 17:543-558
Zhou, Xiaorong; Padanad, Mahesh S; Evers, Bret M et al. (2018) Modulation of Mutant KrasG12D -Driven Lung Tumorigenesis In Vivo by Gain or Loss of PCDH7 Function. Mol Cancer Res :
Abrams, Zachary B; Zucker, Mark; Wang, Min et al. (2018) Thirty biologically interpretable clusters of transcription factors distinguish cancer type. BMC Genomics 19:738
Pietanza, M Catherine; Waqar, Saiama N; Krug, Lee M et al. (2018) Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol 36:2386-2394
Huang, Fang; Ni, Min; Chalishazar, Milind D et al. (2018) Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers. Cell Metab 28:369-382.e5
Tanaka, Ichidai; Sato, Mitsuo; Kato, Toshio et al. (2018) eIF2?, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer. Cancer Sci 109:1843-1852
Pozo, Karine; Minna, John D; Johnson, Jane E (2018) Identifying a missing lineage driver in a subset of lung neuroendocrine tumors. Genes Dev 32:865-867
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646

Showing the most recent 10 out of 1059 publications